Cerebrolysin

Overview

Cerebrolysin is a parenterally administered preparation of enzymatically treated porcine brain-derived peptides, manufactured by EVER Neuro Pharma (formerly Ebewe Pharma), an Austrian pharmaceutical company. The product consists of approximately 75% low-molecular-weight peptides (below 10 kDa) and 25% free amino acids, obtained through standardized biotechnological processing of purified porcine brain proteins.

First developed in the 1970s, Cerebrolysin has accumulated one of the largest clinical evidence bases of any neurotrophic compound, with over 200 clinical studies and extensive use in clinical practice across Europe, Asia, and Latin America. It is approved in more than 40 countries for indications including ischemic stroke, traumatic brain injury (TBI), Alzheimer's disease, and vascular dementia.

However, Cerebrolysin has never received FDA approval in the United States, and its use remains absent from major American and Western European stroke guidelines. This regulatory and geographic divide has made it one of the most debated compounds in neurology — widely prescribed in some regions while virtually unknown in others.

The compound's mechanism is attributed to its neurotrophic factor-like activity. The peptide fractions have been shown to mimic the effects of naturally occurring neurotrophic factors including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF), though the preparation does not contain these proteins themselves.

Structure and Composition

Cerebrolysin is not a single compound but a standardized, complex biological mixture:

Composition:

• Peptide fraction (~75%): Low-molecular-weight peptides below 10 kDa, derived from enzymatic proteolysis of porcine brain proteins
• Free amino acid fraction (~25%): Including glycine, glutamic acid, lysine, alanine, and other standard amino acids
• Molecular weight range: Predominantly 1-10 kDa peptides
• Standardization: Each batch is quality-controlled to ensure consistent peptide profile via HPLC and biological activity assays

Physical properties:

• Amber-colored aqueous solution
• pH approximately 7.0
• Supplied in ampoules of 1, 5, 10, and 30 mL
• Contains 215.2 mg of Cerebrolysin concentrate per mL

The exact peptide sequences within Cerebrolysin have been partially characterized through mass spectrometry studies, revealing fragments derived from tubulin, actin, neurofilament proteins, myelin basic protein, and other brain-specific structural and signaling proteins. However, the complete compositional profile at the sequence level remains incompletely defined.

Mechanism of Action

Neurotrophic Factor-Like Activity

Cerebrolysin's peptide fractions exhibit activity patterns that overlap with those of endogenous neurotrophic factors:

• BDNF-like activity: Activation of TrkB-mediated signaling, promotion of neuronal survival and differentiation
• NGF-like activity: Support of cholinergic neuron survival and function
• GDNF-like activity: Protection of dopaminergic neurons
• CNTF-like activity: Support of motor neuron survival

These activities are attributed not to the presence of intact neurotrophic factors (which would be too large to survive enzymatic processing) but rather to peptide fragments that retain partial activity at neurotrophin receptor systems.

Neuroprotection Pathways

Cerebrolysin has been shown to modulate several neuroprotective pathways:

• Anti-apoptotic signaling: Activation of PI3K/Akt and inhibition of GSK-3β
• Anti-excitotoxicity: Modulation of glutamate receptor signaling and reduction of calcium influx
• Anti-inflammatory: Reduction of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) in injured brain tissue
• Antioxidant: Reduction of oxidative stress markers following ischemic injury

Neuroplasticity Enhancement

• Promotion of dendritic branching and spine density
• Enhancement of synaptic transmission and long-term potentiation
• Stimulation of neurogenesis in the hippocampal subgranular zone
• Upregulation of synaptic vesicle proteins (synaptophysin, synapsin)

Amyloid Modulation

In Alzheimer's disease models, Cerebrolysin has been reported to:

• Reduce amyloid precursor protein (APP) expression
• Decrease amyloid-beta (Aβ) plaque burden
• Modulate secretase activity favoring non-amyloidogenic processing
• Reduce tau hyperphosphorylation

Research Summary

Area	Study	Key Finding	Reference
Acute ischemic stroke	CASTA trial (n=1,070)	No significant difference in primary endpoint (mRS) at 90 days; signal for improvement in secondary endpoints	Heiss et al., 2012
Stroke (early treatment)	E-COMPASS (n=70)	Improved motor recovery at 90 days when administered within 24 hours of onset	Muresanu et al., 2016
Alzheimer's disease	Cochrane meta-analysis	Evidence of benefit on global clinical impression; limitations in trial quality noted	Bae et al., 2018
Traumatic brain injury	CAPTAIN trial (n=32)	Improved recovery scores and reduced biomarkers of neuronal injury	Chen et al., 2013
Vascular dementia	Multi-center trial (n=242)	Improvement in cognitive function (ADAS-cog) at 24 weeks	Guekht et al., 2011
Neonatal brain injury	Phase 2 studies	Improved neurodevelopmental outcomes in neonates with hypoxic-ischemic encephalopathy	Multiple, various
Stroke rehabilitation	Combined with rehabilitation	Enhanced recovery when combined with early rehabilitation protocols	Muresanu et al., 2020
Safety	Pooled safety analysis	Generally well-tolerated; adverse events similar to placebo in controlled trials	Bornstein et al., 2018

Pharmacokinetics

• Administration: Intravenous (IV) infusion or intramuscular (IM) injection; oral administration is ineffective due to gastrointestinal degradation
• Dosing (stroke): Typically 30-50 mL IV daily for 10-21 days, initiated within 24-72 hours of stroke onset
• Dosing (dementia): Typically 10-30 mL IV daily for 20 days per treatment cycle; cycles repeated at intervals
• Dosing (TBI): 30-50 mL IV daily during acute phase
• Blood-brain barrier penetration: Demonstrated in preclinical studies; the low-molecular-weight peptide fraction facilitates CNS entry
• Half-life: Not precisely characterized for the mixture due to its multi-component nature; individual peptide fractions likely have varying elimination kinetics
• Maximum IM injection volume: 5 mL per injection site; larger doses require IV administration

Dosing Protocols

The following dosing information is compiled from published research and community discussion for educational purposes only. No FDA-approved human dosing guidelines exist for most research peptides. Always consult a qualified healthcare professional.

Reconstitution

Parameter	Value
Vial size	60 mg
Bacteriostatic water	3.0 mL
Concentration	20 mg/mL
Storage (reconstituted)	2-8 °C, use within 7 days
Storage (lyophilized)	Room temperature, do not exceed 25 °C

Dosing Schedule

Phase	Dose	Frequency	Duration
Starting	20 mg	Once daily	Week 1
Mid-range	24 mg	Split AM/PM	Week 2
Escalation	28 mg	Split AM/PM	Week 3
Target	32 mg	Split AM/PM	Weeks 4-12

Syringe Measurements (U-100 insulin syringe)

Dose	Units	Volume
20 mg	100 units	1.00 mL
24 mg (split)	60 units AM + 60 units PM	0.60 mL each
28 mg (split)	70 units AM + 70 units PM	0.70 mL each
32 mg (split)	80 units AM + 80 units PM	0.80 mL each

Cycle Guidelines

• Cycle length: 8-12 weeks (up to 16 weeks)
• Route: Subcutaneous injection
• Split dosing rule: Injections exceeding 100 units (1.0 mL) should be split into AM/PM doses at different sites
• Titration: Increase by ~4 mg (20 units) per week
• Injection sites: Rotate between abdomen, thighs, and upper arms

Common Discussion Topics

Regulatory Divide

Cerebrolysin's absence from FDA approval and Western European stroke guidelines, despite over 200 clinical studies, is a frequent discussion point. Critics point to the inconsistency of primary endpoint results in large trials (notably CASTA), methodological limitations in many studies, and the complexity of evaluating a multi-component biological product by modern regulatory standards. Proponents argue that the accumulated body of evidence across multiple indications demonstrates clinically meaningful neurotrophic activity.

Biological Complexity and Standardization

As a biological preparation rather than a single chemical entity, Cerebrolysin presents unique challenges for characterization and quality control. While the manufacturing process is standardized, the inability to precisely define every active component creates difficulties for regulatory approval in markets that favor single-entity pharmaceuticals with defined mechanisms.

Evidence Quality

Systematic reviews have noted that while many Cerebrolysin trials show positive signals, issues with study design, sample size, and potential publication bias limit the strength of conclusions. The Cochrane review of Cerebrolysin for Alzheimer's disease noted evidence of benefit but emphasized the need for larger, well-designed confirmatory trials.

Comparison to Synthetic Neurotrophic Agents

Cerebrolysin is sometimes compared to single-entity neurotrophic compounds such as Dihexa or PE-22-28. The multi-component nature of Cerebrolysin may provide a broader spectrum of neurotrophic activity but makes mechanistic attribution difficult. Synthetic compounds offer clearer structure-activity relationships and more straightforward regulatory paths.

Related Compounds

• Dihexa — A synthetic HGF/c-Met agonist studied for cognitive enhancement with a defined single-entity mechanism
• PE-22-28 — A synthetic TREK-1 blocker studied for antidepressant and cognitive effects
• Thymalin — Another tissue-derived peptide preparation (thymic) studied for systemic effects, sharing the paradigm of biological extract-based therapeutics